RVNC - Revance Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (5Y Monthly) 1.22
52-Week Change 331.29%
S&P500 52-Week Change 325.78%
52 Week High 323.43
52 Week Low 39.88
50-Day Moving Average 317.95
200-Day Moving Average 314.59

Share Statistics

Avg Vol (3 month) 3686.93k
Avg Vol (10 day) 3694.07k
Shares Outstanding 553.4M
Float 37.62M
% Held by Insiders 11.40%
% Held by Institutions 192.93%
Shares Short (Dec 30, 2019) 46.59M
Short Ratio (Dec 30, 2019) 47.3
Short % of Float (Dec 30, 2019) 423.13%
Short % of Shares Outstanding (Dec 30, 2019) 412.53%
Shares Short (prior month Nov 28, 2019) 45.72M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)-19,320.84%

Management Effectiveness

Return on Assets (ttm)-39.26%
Return on Equity (ttm)-92.82%

Income Statement

Revenue (ttm)811k
Revenue Per Share (ttm)0.02
Quarterly Revenue Growth (yoy)-98.10%
Gross Profit (ttm)3.73M
EBITDA -154.06M
Net Income Avi to Common (ttm)-154.72M
Diluted EPS (ttm)-3.76
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)209.03M
Total Cash Per Share (mrq)4.63
Total Debt (mrq)30.09M
Total Debt/Equity (mrq)19.89
Current Ratio (mrq)6.46
Book Value Per Share (mrq)3.43

Cash Flow Statement

Operating Cash Flow (ttm)-103.79M
Levered Free Cash Flow (ttm)-88.16M